Colorectal Cancer

P=N/A, N=106, Recruiting, Sixth Affiliated Hospital, Sun Yat-sen University | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2025 --> Jun 2027

Adjuvant chemotherapy may significantly increase the risk of BT after ileostomy closure following colorectal cancer surgery.

Notably, NPM1 expression correlates with elevated WNT signaling and proliferation in human colorectal cancer (CRC), while CRCs harboring NPM1 deletions exhibit preferential TP53 inactivation, underscoring the clinical relevance of our findings. Being dispensable for adult epithelial homeostasis, NPM1 represents a promising therapeutic target in p53-proficient WNT-driven tumors, including treatment-refractory KRAS-mutant CRC, and hepatic cancers.

Consistently, low USP7 expression is associated with a better response to anti-PD-1 therapy. Overall, we propose a novel DUB-based classification system for MSS CRC and demonstrate that targeting USP7 may overcome immunotherapy resistance by converting immunologically "cold" tumors into "hot" ones.

Overall, liposomal co-delivery maintains DOX cytotoxicity while strengthening G₁/S checkpoint blockade and increasing programmed cell death, with partial moderation of DNA fragmentation. These in-vitro data motivate stability optimization and in-vivo evaluation in CRC models.

CD44 and p-ERK1/2 co-expression defines a high-risk subset of CRC patients with increased metastatic potential. These findings highlight a clinically relevant biomarker axis that may aid in prognostic stratification and future therapeutic targeting.

Notably, SLC38A5 depletion sensitizes CRC cells to RSL3-induced ferroptosis...Our findings reveal a novel mechanism wherein SLC38A5 confers ferroptosis resistance in CRC via YAP nuclear translocation within the Hippo signaling pathway. Collectively, this study highlights SLC38A5 as a potential therapeutic target to enhance ferroptosis-based cancer therapy, offering new strategies to improve CRC treatment outcomes.

Importantly, unlike the ROS scavenger N-acetylcysteine (NAC), which decreased the anticancer effectiveness of both oxaliplatin and paclitaxel, formononetin maintained their anticancer effects in colorectal cancer HT29 cells and cervical cancer SiHa cells. Taken together, formononetin holds potential as a neuroprotectant to prevent oxaliplatin-induced neurotoxicity without compromising anticancer efficacy.

No new IRRs nor toxic deaths were reported. ENCO-PANI appears to be as safe and effective in pts treated for a BRAFm mCRC unable to continue CET and may represent a valid alternative therapeutic option in this setting.

Furthermore, KDM6A inhibition in combination with cisplatin, resulted in an increased tumor regression in vivo. Our study thus highlights the importance of KDM6A as a therapeutic target in preventing CRC growth and relapse which can have future therapeutic implications.

Clinically, UCHL3 and SIPA1 were found to be upregulated in CRC tissues, whereas ITCH was downregulated, with their expression correlating with poor patient prognosis. Altogether, the findings of this study reveal the novel UCHL3-ITCH-SIPA1 regulatory axis that modulates oncogenic signaling and CRC progression, offering new insights into the post-translational regulation of SIPA1 and identifying potential therapeutic targets.

ZLN suppresses CEC ferroptosis by inhibiting ALOX15/15(S)-HPETE to repress colorectal tumorigenesis and progression, providing a rationale for employing ZLN as a potential therapeutic approach.